On Adaptive Interventions and SMART Inbal (Billie) Nahum-Shani



Outline


- Adaptive Intervention (AIs)
 - What they are
 - Components
 - Motivation
- Sequential Multiple Assignment Randomized Trial (SMART)
 - How it can be used to inform the development of AIs
 - Key features
 - Sample size considerations
 - SMARTs vs. other designs
 - Examples of SMARTs

Outline

- Adaptive Intervention (AIs)
 - What they are
 - Components
 - Motivation
- Sequential Multiple Assignment Randomized Trial (SMART)
 - How it can be used to inform the development of AIs
 - Key features
 - Sample size considerations
 - SMARTs vs. other designs
 - Examples of SMARTs

Definition of AI

- An intervention design
- ...in which intervention options are individualized to accommodate the specific and changing needs of individuals.
- A sequence of individualized treatments.
- Mimics how we make decisions in real-life
- ... but aim to guide decision making in clinical, educational, health policy etc.



Definition of AI

- Go by many different names:
 - Adaptive health interventions,
 - Adaptive treatment strategies,
 - Dynamic treatment regimes (DTRs),
 - Treatment algorithms,
 - Stepped care models,
 - Treatment protocols,
 - Individualized interventions

– ...

Example


- Adaptive drug court program for drug abusing offenders
 - The goal: Minimize recidivism and drug use
 - Operationalized by graduating from the drug court program
 - Marlowe et al., (2008; 2009; 2012)




Nahum-Shani, I.

6

Adaptive Drug Court Program



Adaptive Drug Court Program



Nahum-Shani, I.

```
At point of entry into the program

If risk = low

Then, stage 1 intervention= {As-needed + SC}

Else if risk=high

Then, stage 1 intervention = {Bi-weekly + SC}
```

At point of entry into the program 4

If risk = low

Then, stage 1 intervention= {As-needed + SC}


Else if risk=high

Then, stage 1 intervention = {Bi-weekly + SC}

1. Decision Point:

A time in which treatment options should be considered based on patient information

Adaptive Drug Court Program



```
At point of entry into the program

If risk = low

Then, stage 1 intervention= {As-needed + SC}

Else if risk=high

Then, stage 1 intervention = {Bi-weekly + SC}
```

2. Tailoring Variable:

Patient information used to make treatment decisions

At point of entry into the program

If risk = low

Then, stage 1 intervention= {As-needed + SC}

Else if risk=high

Then, stage 1 intervention = {Bi-weekly + SC}

3. Intervention options:

Type/Dose

4. Decision rule

At point of entry into the program

```
If risk = low
Then, stage 1 intervention= {As-needed + SC}
Else if risk=high
Then, stage 1 intervention = {Bi-weekly + SC}
```

```
At point of entry into the program

If risk = low

Then, stage 1 intervention= {As-needed + SC}

Else if risk=high

Then, stage 1 intervention = {Bi-weekly + SC}
```

5. Outcomes:


Distal → Long-term goal of intervention:

Program graduation (14 consecutive weekly negative drug urine specimens)

Proximal → Short-term goal of decision rules:

Compliance and response in the course of intervention (mediator)

Adaptive Drug Court Program



```
At point of entry into the program

If risk = low

Then, stage 1 intervention= {As-needed + SC}

Else if risk=high

Then, stage 1 intervention = {Bi-weekly + SC}
```

5. Outcomes:

Distal → Long-term goal of intervention:

Program graduation (14 consecutive weekly negative drug urine specimens)

Proximal → Short-term goal of decision rules:

Compliance and response in the course of intervention (mediator)

Proximal outcomes

- Based on your theory of change
- Related to prevention, treatment, academic-success
- At various levels: patient, family, clinic

AI: 5 Elements

1. Decision Points	∢ ······		Triggered
2. Tailoring Variable3. Decision rule4. Intervention Optic	•	Individualizing	Adaptation process
5. Proximal + Distal C	Outcomes <		Guided

Motivation for Adaptive Interventions

- 1. High **heterogeneity** in need/response to any one intervention
- 2. Improvement is **non-linear**
- 3. Intervention burden
- 4. Intervention **cost**

Summary

- Adaptive Intervention is:
 - a sequence of individualized intervention options
 - that uses dynamic information to decide what type/dose/modality of intervention to offer
 - Its objective to guide clinical/academic practice or public health policy.

AI is a sequence of (individualized) treatments

AI is a sequence of decision rules that recommend what to offer, for whom, and when.



Summary

- Adaptive Intervention is:
 - a sequence of individualized intervention options
 - that uses dynamic information to decide what type intervention to offer
 - Its objective to guide clinical/academic practice or public health policy.

AI is a sequence of (individualized) treatments

AI is a sequence of decision rules that recommend what to offer, for whom, and when.



The Role of the Researcher

Develop good decision rules to guide clinical/academic practice and policy

Answer **open scientific questions** concerning the development of good decision rules



Examples of Scientific Questions

- How long should we use the first treatment?
- What tactic should we use for non-responders to treatment A?
- What tactic should we use for responders to treatment A
- How to re-engage patients who are non-adherent or drop-out?
- Location of treatment?
- Mode of delivery?
- How to define non-response?

My Reading List (Not Complete)

- Collins, L. M., Murphy, S. A., & Bierman, K. L. (2004). A conceptual framework for adaptive preventive interventions. *Prevention science*, *5*(3), 185-196.
- Davidian, M., Tsiatis, A. B., & Laber, E. (2016). Dynamic Treatment Regimes. In George, S.L., Wang, X., Pang, H. (Eds.). *Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis*; Chapman & Hall; 409.
- Lavori, P. W., & Dawson, R. (2004). Dynamic treatment regimes: practical design considerations. *Clinical trials*, *I*(1), 9-20.
- Lei, H., Nahum-Shani, I., Lynch, K., Oslin, D., & Murphy, S. A. (2012). A" SMART" design for building individualized treatment sequences. *Annual review of clinical psychology*, 8, 21-48.
- McKay, J. R. (2009). *Treating substance use disorders with adaptive continuing care*. American Psychological Association.

Other questions about Adaptive Intervention? ...

Outline


- Adaptive Intervention (AIs)
 - What they are
 - Components
 - Motivation
- Sequential Multiple Assignment Randomized Trials (SMART)
 - How it can be used to inform the development of AIs
 - Key features
 - Sample size considerations
 - Examples of SMARTs
 - SMARTs vs. other designs

What is a SMART?

- A <u>Multi-Stage Randomized trial</u> (Dawson & Lavori, 2004; Lavori & Dawson, 2001; Murphy, 2004)
- Each stage corresponds to a scientific question(s) concerning the selection and adaptation of intervention options.
- Randomization occurs at each decision point of scientific interest
- Some (or all) participants are randomized more than once, often based on earlier covariates

The goal is to inform the construction of effective adaptive interventions

AIM-ASD SMART (N=192; R01-HD073975; PI: Kasari)




SMART Design Principles

• When to consider a SMART?

- When you would like to address questions concerning the construction of an adaptive intervention
- *Multiple* questions are of interest, regarding multiple decision points

AIM-ASD SMART (N=192; R01-HD073975; PI: Kasari)




SMART Design Principles

• Should re-randomization be restricted?

- If you have ethical, scientific, or practical reason to do so.
 - Ethical: certain treatment options are not appropriate for a subset of the participants
 - Scientific: based on empirical evidence the best treatment for a specific subset of participants is already established
 - Practical: e.g., save the more intense/costly (step-up) options to those who need it most.

AIM-ASD SMART (N=192)



SMART Design Principles

How to select Aims?


- Select a <u>primary aim</u> that is important to the development of an adaptive intervention; sample size is based on this aim
- Collect additional data that could be used to further inform the development of adaptive interventions in <u>secondary aims</u>

Primary Aim: Example 1

Compare initial intervention options

H1: Starting an AI with JASP+EMT will improve social communication more than starting with DTT.

H1: Comparison of Stage 1 Options




Primary Aim: Example 2

Compare second stage options for slow-responders

H2: Blending JASP+EMT and DTT for slower responders will improve social communication more than continue.


H2: Stage 2 Options for Slow Responders




Primary Aim: Example 3

Campore embedded adaptive interventions


....first let's review what we mean by "embedded adaptive intervention"








Start with DTT Then, at week 6 If response status = responder Then, stage 2 intervention= {add Parent Training} Else if response status = slow responder Then, stage 2 intervention = {Blend with JASP+EMT}

Scale of Improvement









...and so on...

...Embedded Adaptive Interventions 5, 6, 7, and 8 are similar but begin with JASP+EMT...


Primary Aim: Example 3

Compare embedded adaptive interventions

H3: The AI that begins with JASP+EMT and (a) adds parent training for responders and (b) blends for slower responders...

...will improve social communication more than the similar AI which begins with DTT.

H3: Comparison of 2 AIs



Primary aim Examples

1: Compare initial intervention options:

H1: JASP+EMT is better than DTT

2: Compare subsequent options among slow responders:

H2: Blending is better than Continue

3: Compare embedded AIs:

H3: AI #1 is better than AI #5

Sample Size

H1: Initial intervention options:

JASP+EMT is better than DTT.

• Sample size formula is same as for a two group comparison.

H2: Subsequent options among slow responders: Blending is better than Continue.

• Sample size formula is same as a two group comparison of slow responders.

Sample Size Examples

N =sample size for the <u>entire</u> trial

H1

H2

$$\Delta \mu / \sigma = .3$$

$$\Delta \mu / \sigma = .5$$

N = 350 N	r = 350/ SR rate
-------------	------------------

$$N = 126$$

$$N = 126/SR$$
 rate

 $\alpha = .05$ (two sided), power = $1 - \beta = .80$

^{*} Assumptions: equal variances, normality, equal # in each group, no dropout.

^{**} AIM-ASD's was of this type, w/ ES = 0.5, pwr = 90% and acctng for 10% dropout.

Sample Size Examples

H3: AI #1 results in better social communication compared to AI #5

- Sample size formula depends on who gets re-randomized
- If both R and SR get re-randomized

Type I error rate (2-sided)	Power	Standardized Difference	N	Randomization
0.05	80%	0.3	698	Both R and SR are
		0.5	252	re-randomized

- Continuous Outcomes: Oetting, A.I., et al. (2011)
- Survival Outcomes: Feng, W. and Wahed, A., (2009); Li, Z. and Murphy, S.A., (2011)
- *Binary Outcomes:* Kidwell, K.M., et al. (under review)


Secondary Aim: Example

Identify ways to more deeply-tailor the AI.

– Example:

H4: Among early responders, those whose parents demonstrate greater buy-in for the initial treatment will benefit more from parent training than from continue.

More Deeply Tailored?




Start with DTT Then, at week 6 If response status = responder Then, stage 2 = {add Parent Training} Else if response status = slow responder Then, stage 2 = {Blend with JASP+EMT}

C. I. C.

Scale of Improvement

Parent Buy-in as a Tailoring Variable?



Example of a More Deeply Tailored AI

```
Start with DTT

Then, at week 6

If response status = responder

Then,

If parent buy-in={high}

Then, stage 2 = {add Parent Training}

Else, if parent buy-in={low}

Then stage 2 = {add parent training or continue}

Else if response status = slow responder

Then, stage 2 = {Blend with JASP+EMT}
```

Methods for Analyzing Data

- Compare first and second-stage intervention options
- Compare AIs with end of study outcome (e.g., Nahum-Shani et al., 2012a)
- Multiple comparisons with the best embedded AI (e.g., Ertefaie et al., 2015)
- Compare AIs with repeated measures outcomes (e.g., Lu et al., 2015)
- Identify ways to more deeply tailor embedded AIs (e.g., Nahum-Shani et al., 2012b; Schulte et al., 2014)


SMARTs vs. Other designs

- RCT
- Non-Responders studies
- Factorial Designs
- Crossover
- Adaptive Trials
- Randomized Discontinuation Design

SMART vs. Randomized Control trial (RCT)


- A randomized control trial (RCT) evaluating an AI compared to a suitable control.
 - The primary aim is to confirm it's effectiveness compared to an alternative

The Multiphase Optimization Strategy (MOST)





SMART vs. Non-Responders Trial

- Randomizing non-responders to a given intervention to subsequent intervention options
 - Evidence is sufficient to select a first-line treatment; but there are scientific questions regarding subsequent options for non-responders
 - Also known as the 'single-stage-at-a-time approach"
 - There are various considerations when building an adaptive intervention based on a series of separate responder or non-responder trials.



SMART vs. Non-Responders Trial






Scale of Improvement

- 1. Delayed effects
- 2. Drop-out
- 3. Selection effects
- 4. Prescriptive effects

SMARTs vs Factorial Experiments


- A SMART is a special form of a factorial; factors are employed sequentially.
- Randomization to subsequent factors in a SMART are often restricted based on early response status
- In SMART, effects have <u>sequential</u> <u>interpretation</u>.

		Treatment A			
_		NO NO	YES		
Treatmen B	NO it	Neither A nor B	A only		
	YES	B only	Both A and B		



SMARTs vs Crossover Trials


• A repeated measurements design-- patients cross over from one treatment to another during the course of the trial.



- Typically aim to evaluate standalone treatments, not to address questions concerning AIs
- Attempts to wash out the carryover effects while SMARTs are often motivated by such (delayed)

SMARTs vs Adaptive Trials/Designs

- A clinical trial design that allows adaptations or modifications to aspects of the trial while the study is still ongoing (Chang, 2007)
- e.g.,
 - Stop the trial early either for success, futility or harm
 - Drop arms or doses or adjust doses
 - Modify randomization rate to increase probability of allocation to the most appropriate arm
- SMARTs are generally not adaptive designs
 - Design parameters are set a-priori
 and do not change.
 - But the two concepts can be combined (Cheung et al., 2015; Lee et al., 2015)




SMARTs vs Randomized Discontinuation Trial (RDT)

• A SMART follows all patients who enroll, whereas RDT does not continue to follow participants who are not randomized

• The focus of RDT is on whether we should continue or discontinue


treatment for responders to stage 1.



Other Interesting SMARTs

- ExTENd
 - N=302; NIAAAOSL014851; PI: Oslin
- ENGAGE
 - N=500; P60DA05186; PI: McKay
- SMARTer
 - N=400; R01DK108678; PIs: Spring & Nahum-Shani

ExTENd




ENGAGE

First-stage Intermediate Second-stage Experimental intervention intervention **Conditions** outcome Engaged No further contact MI-IOP MI-PC Non-No further contact engaged Engaged -No further contact MI-PC MI-PC Nonengaged No further contact Week 2 0 Week 8 Month 6

MI-IOP→ motivational interviewing that focuses on helping the patient to engage in the IOP

MI-PC→ motivational interviewing that includes a choice of four possible treatment options

SMARTer



App→ Mobile Application

MR→ Meal Replacement

TXT→ Text Messages

...and Many Other SMARTs in the field...


- Drug abuse
- ADHD
- Alcoholism
- Obesity
- OCD
- Autism

- Schizophrenia
- Depression
- Insomnia
- Bipolar
- Conduct problems
- Smoking cessation
- Suicide prevention

https://methodology.psu.edu/ra/adap-inter/projects

SMART and **MOST**

The Multiphase Optimization Strategy (MOST)



The End

Inbal (Billie) Nahum-Shani

Email: inbal@umich.edu

Thank you...

Danny Almirall

Susan Murphy

John Dziak

Jim McKay

Kevin Lynch

Linda Collins

Bonnie Spring

Kelley Kidwell

R01 DA039901 (Nahum-Shani & Almirall

R01 AA022113 (Bacharach)

U54-EB-020404 (Kumar)

R01 AA023187 (Murphy)

P50 DA039838 (Collins)

R01 DK108678 (Spring & Nahum-Shani)

R01 HD73975 (Kasari)

R01-MH103244 (King)